
- Description
- Additional
Description
Details
Description:Mouse monoclonal antibody against Thr181 phosphorylated Tau protein
Purification:Protein G affinity purified
Target Protein:Human Thr181 phosphorylated Tau
Immunogen:KLH conjugated with a short peptide [Ala-Pro-Lys-Thr(p)-Pro-Pro-Ser-Ser-Gly-Glu-Cys], corresponding to the amino acid sequence 177-187 on the phosphorylated Tau protein.
Fusion Myeloma:Sp2/0-Ag14
Specificity:This antibody reacts with the unconjugated Thr181 phosphorylated Tau peptide.
Species Reacitvity:Human, mouse
Host / Isotype: Mouse, IgG1 Kappa
Formulation:Lyophilized from a solution in 0.01M PBS pH7.2
Reconstitution:Double distilled water is recommended to adjust the final concentration to 1.00mg/mL. Avoid repeated freeze and thaw cycle.
Storage: Store at -20oC
Research Area:Alzheimer’s disease and other neurodegenerative diseases
Background:
Tau is a highly soluble microtubule associated protein found in high concentration in neuron of central nervous system. The main function of the protein is stabilizing the microtubule in nerve fibre (axon). There are six tau isoforms which are formed by alternate splicing. Hyperphosphorylation of Tau protein results in aggregation and formation of neurofibrillary tangles, which is significantly associated with cognitive impairment in Alzheimer’s disease. Tau Thr181 phosphorylation has been used as a biomarker for the differentiation of Alzheimer’s disease and other primary dementia such as dementia with Lewy bodies..
Application:
1.Indirect ELISA: The antibody reacts with phosphorylated peptide [Ala-Pro-Lys-Thr(p)-Pro-Pro-Ser-Ser-Gly-Glu-Cys] coated ELISA plate in indirect ELISA. Cross-reactivity with un-phosphorylated peptide is very low.
2. Western Blot:The antibody detected a 46kD band in mouse brain tissue lysate.
Detect the mouse brain tissue lysates using antibody (Tau-pho181 9B4) at 1:2000 (0.5 μg/mL) dilution.
References:
If research is published using this product, please inform Anogen in order to cite the reference on this datasheet. Anogen will provide one unit of product in the same category as gratitude.
Additional
Additional Information
Product Specificity | mAb anti-Thr181 Phosphorylated Tau, 9B4 |
---|---|
Application | EIA, WB |
Size | 0.1 mg |
ebiomall.com






>
>
>
>
>
>
>
>
>
>
>
>
以BD出品的为例,你可以购买现成的或者可以根据你要检测的不同细胞因子和厂家定制bead array。基本原理就是试剂盒含有多种微球,每一种都是两种不同荧光强度组合,所以在流式检测的时候会形成一个矩阵。每种微球上附着有可以识别一种细胞因子的抗体。和样本孵育后,再加入荧光标记的抗不同细胞因子的抗体(同样颜色)。这样,只要微球上结合有细胞因子,这个微球就会有三种荧光了。
前两种荧光来判断是哪种微球(哪种细胞因子),第三种荧光是识别抗体上的,来定量。试剂盒还会提供标准品,用来做标准曲线。
现分享于此:
LatexBeadsPhagocytosisassay
---Materials
*Fluorescencelabeledlatexbeads(1umdiameter),2.5%aqueoussUSPension
*3%BSAcontaining25mMNa2HPO4,pH6.0
*0,3%(w/v)azide
*Culturemediumcontaining5%FBS
*Distilledwater,PBS
*Bathsonication,6(12)-wellplates
---Cellcultureandtreatment
1,Inoculateplateswith7,0104cells/cm2perwell.Incubateat37℃,5%CO2for24hr,bestuntil50-70%confluenceisreached
2,Removeculturemediumandexposethecellstotestmaterial.Incubateat37℃,5%CO2for24hr.
---Preparationofcoatedlatexbeads
1,Washlatexbeadswithdistilledwaterandpelletat10,000gfor8minatRT.
2,Resuspendlatexbeadsin3%BSAcontaining25mMNa3PO4(pH6.0)andincubateatRTfor15minwithbathsonication.
*CoatingbeadsinBSAinsuresbeadsremaininamonodispersestate.
3,Washthebeadsoncewithculturemediumcontaining5%FBS.
4,Resuspendthebeadsinculturemediumatconcentration2.0%.Thisisbeadsstock.Storedindarknessat4℃.
---Assay
1,Controlsandsamples:Intactcontrol(Nostaining)1well
-Negativecontrol(azidetreated)1well
-Normalcontrol1well
-sample5wells
*Inordertodifferentiatebetweenphagocytosedbeadsandbeadsnonspecificallyadheretothecellsurface,controlcellsareexposedto0,3%(w/v)azidefor10minpriortotheadditionofcoatedbeads.Thistreatmentcompromisesmicroglialenergeticprocessesandfewbeadswereinternalizedasobservedbyfluorescentmicroscopy.Meanfluorescenceofazide-treatedmicrogliawasusedasthenegativecontrolandwassubtractedfromvaluesobtainedinexperimentalsamples.
2,Forexperimentsusing6well-plates,15μlbeadsstockin1mlculturemediumisappliedtoeachwell.Votexthebeadsstockwellandtakeout105μlandaddinto7mlculturemedium.Bathsonificatefor10minatRTindarkness.Thisisbeadsworkingsolution.
Forexperimentsusing12well-plates,6μlbeadsstockin0.4mlculturemediumisappliedtoeachwell.
3,WasheachwelltwicewithPBSandreplacewithbeadsworkingsolution,1ml/wellfor6-wellplate,0.4ml/wellfor12well-plate.Incubateinthedarkat37℃for80-120min.
4,Removebeadsworkingsolutionandwash3timeswithPBStoremoveexcessbeads.
5,LiftthecellsbyscrappingortrypsinizationandwashthecellswishPBS.
6,StainwithPI(4ug/mlfinalconcentration)andrunforFACS.
对于六分之一效率(99.9999%)ULPA过滤器,该系统挑战将产生100个粒子/ 立方英尺的下游气溶胶浓度或将在标称1.0cfm激光粒子计数器(LPC)中产生100个粒子/分钟的计数速率。
过滤器效率以及过滤器中任何相关联的泄漏可以通过LPC简单地检测。标准集团的高输出PSL气溶胶发生器取代了传统过滤器测试和无尘室认证中使用的DOP(邻苯二甲酸二辛酯)和其他油基气溶胶发生器。
靶向性——脂微球载体以其特有的亲和力聚集于病变部位;
持续性——在脂微球的保护作用下,前列地尔主要在肺部的灭活明显降低;
高效性——仅需传统剂型几十分之一的给药量,且疗效更佳;
低副作用——在脂微球的屏障作用下,前列地尔对血管的刺激和炎性反应明显减少;
“脂微球保护技术”的引入,使得优帝尔的剂型稳定性更高,用药更安全:
剂型稳定性更高——优帝尔仅需在阴凉处(不超过20℃)保存,这样带来的好处是:南方地区无需冷藏储存,北方地区也不用再担心药物因温度过低而冻结,从而影响临床用药。(蓓畅、凯时等同类产品在运输、贮藏过程中必须保证环境温度范围在0-5℃)
用药更安全——市场上已有北京泰德制药有限公司生产的“前列地尔注射液”,商品名“凯时”,该品种也是运用脂微球化技术的一类制剂。但是该品种由于自身生产工艺的缺点,其中的主要杂质—PGA1相当高,质量标准中规定其限度高达60%,对产品中其他杂质也未进行控制。而药友公司通过长达近10年的摸索,通过无菌过滤和低温冷冻干燥技术,制备的“注射用前列地尔干乳剂”可将杂质PGA1严格控制在10%以内,其他杂质控制在1%以内,表明药友公司采用的冷冻干燥方法更加有利于产品的质量控制。因此药友公司注射用前列地尔干乳剂提出了比“凯时”更为严格的质量标准要求,有效保证产品质量。由于本品质量的提升,使得本品可以储存在常见的阴凉条件下,而不是“凯时”相当苛刻的储存条件要求。药友公司技术人员通过大量科学研究,探索出特殊的冻干保护剂和严格的冻干过程控制实现了脂微球的冻干技术,使本品既保留了脂微球的物理性质,又显著提升了脂微球的化学稳定性。因此,“优帝尔”的执行标准仅为前列地尔注射液执行标准的六分之一。
细胞内的蛋白,用荧光标记的单克隆抗体识别后,用流式可以测出每个细胞的相对荧光强度。有一种特异性的微球,可以吸附一系列不同定量分子数的抗体。这种微球吸附同样的荧光抗体,可以做出荧光强度和所吸附抗体分子数量的标准曲线。然后拿细胞检测的荧光强度和这个标准曲线对比,得到细胞内所结合的抗体数。因为单克隆抗体只结合相同的抗原表位,所以可以推算出细胞内蛋白的分子数量了。
解释结果的时候要考虑到抗体的特异性和染色的效果等影响因素。
目前国内的制药企业对微粒释放系统的立项开发越来越多,园子里已经就脂质体展开了很多火热的讨论,我个人也参与其中,大家交流经验,取长补短,渐渐的找到了方向,系统而固定的讨论交流是非常有好处的。
因此在此倡议建立一个微球的交流区,让大家相互交流比如:微球产业化、技术难点、实验中遇到的问题、相关理论的探讨、最新进展交流等等

